



Revision date 18-Mar-2022 Version 2 Page 1/14

# Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

#### 1.1. Product identifier

Product Name Linezolid Injection (Hospira, Inc.)

Product Code(s) PZ03154
Trade Name: Not applicable
Chemical Family: Mixture

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

#### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045 1-800-879-3477

OSG Building Ringaskiddy, Co. Cork.

Pfizer Ireland Pharmaceuticals

Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

#### 1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

# Section 2: HAZARDS IDENTIFICATION

# 2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous

2.2. Label elements

Signal word Not required

**Hazard statements** Non-hazardous in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

Revision date 18-Mar-2022 Version 2

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2/14

# Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

**Substances** 

Not applicable

#### 3.2 Mixtures

Hazardous

Chemical name  Linezolid (CAS #: 165800-03-3)	Weight-%	REACH Registration Number	EC No  Not Listed	Classification according to Regulation (EC) No. 1272/2008 [CLP] STOT RE 2 (H373) Aquatic Acute	Specific concentration limit (SCL)	M-Factor  No data available	M-Factor (long-term) No data available
, i				2 (H401) Aquatic Chronic 2 (H411)			
Citric acid (CAS #: 77-92-9)	*		201-069-1	Eye Irrit. 2A (H319)SE 3 (H335)	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available
NonHazardous Chamical name	Moight 9/	REACH	EC No	Classification	Chaoifia	M-Factor	M-Factor
Chemical name	Weight-%	REACH Registration Number		according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)		(long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
Dextrose	*		Not Listed	Not classified	Not Listed	No data	No data

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

(CAS #: 14431-43-7)			as hazardous		available	available
SODIUM CHLORIDE (CAS #: 7647-14-5)	-	231-598-3	Not classified as hazardous	Not Listed	No data available	No data available

#### Full text of H- and EUH-phrases: see section 16

#### **Acute Toxicity Estimate**

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Citric acid 77-92-9	5400	>2000	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available

Additional information

- + Substance with a Union workplace exposure limit
- \* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Page 3/14

Version 2

# Section 4: FIRST AID MEASURES

#### 4.1. Description of first aid measures

**Inhalation** Remove to fresh air. Seek immediate medical attention/advice.

**Eye contact** Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

**Skin contact** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

#### 4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

# 4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

<sup>\*\*</sup> to adjust pH

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

Revision date 18-Mar-2022 Version 2

# Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products

Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for

fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Page 4/14

Use personal protection equipment.

# Section 6: ACCIDENTAL RELEASE MEASURES

#### 6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

#### Section 7: HANDLING AND STORAGE

#### 7.1. Precautions for safe handling

#### Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors. HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

#### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

#### 7.3. Specific end use(s)

Page 5/14 Version 2

STEL: 4 mg/m<sup>3</sup>

# Specific use(s)

Pharmaceutical drug product.

# Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1. Control parameters

#### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

Pfizer OEL TWA-8 Hr: 750 µg/m<sup>3</sup>

Citric acid

Czech Republic 4 mg/m<sup>3</sup> 2 mg/m<sup>3</sup> Germany

Ceiling / Peak: 4 mg/m<sup>3</sup> Germany 2 mg/m<sup>3</sup> MAČ: 1 mg/m<sup>3</sup> Russia Switzerland 2 mg/m<sup>3</sup>

Sodium hydroxide

ACGIH OEL (Ceiling)  $2 \text{ mg/m}^3$ **ACGIH TLV** Ceiling: 2 mg/m<sup>3</sup>

2 mg/m<sup>3</sup> Austria STEL 4 mg/m<sup>3</sup> 2.0 mg/m<sup>3</sup> Bulgaria Czech Republic 1 mg/m<sup>3</sup>

Ceiling: 2 mg/m<sup>3</sup> Ceiling: 2 mg/m<sup>3</sup> Denmark Estonia 1 mg/m<sup>3</sup>

STEL: 2 mg/m<sup>3</sup> Finland Ceiling: 2 mg/m3 2 mg/m<sup>3</sup> France Hungary 1 mg/m<sup>3</sup> STEL: 2 mg/m<sup>3</sup> Ireland STEL: 2 mg/m3

Ceiling Limit Value 2 mg/m<sup>3</sup> Latvia 0.5 mg/m<sup>3</sup> Poland STEL: 1 mg/m<sup>3</sup> 0.5 mg/m<sup>3</sup> Romania 1 mg/m<sup>3</sup>

STEL: 3 mg/m<sup>3</sup> Slovakia 2 mg/m<sup>3</sup> Spain STEL: 2 mg/m3 Switzerland 2 mg/m<sup>3</sup> STEL: 2 mg/m3

**OSHA PEL** 2 mg/m<sup>3</sup>

(vacated) Ceiling: 2 mg/m3 United Kingdom STEL: 2 mg/m<sup>3</sup>

+ Hydrochloric Acid

ACGIH OEL (Ceiling) 2 ppm **ACGIH TLV** Ceiling: 2 ppm

Austria 5 ppm 8 mg/m<sup>3</sup> STEL 10 ppm STEL 15 mg/m<sup>3</sup> Bulgaria STEL: 10 ppm

STEL: 15.0 mg/m3 5 ppm

8.0 mg/m<sup>3</sup>

**European Union** 

Czech Republic 8 mg/m<sup>3</sup>

Ceiling: 15 mg/m<sup>3</sup>

Estonia 5 ppm 8 mg/m³

STEL: 10 ppm STEL: 15 mg/m<sup>3</sup> TWA: 5 ppm

TWA: 8 mg/m³
STEL: 10 ppm
STEL: 15 mg/m³
Finland
STEL: 5 ppm

 $\begin{array}{ccc} & & \text{STEL: 7.6 mg/m}^3 \\ \text{Germany} & & 2 \text{ ppm} \end{array}$ 

Germany 2 ppm 3.0 mg/m<sup>3</sup>

Ceiling / Peak: 4 ppm Ceiling / Peak: 6 mg/m<sup>3</sup>

Germany 2 ppm 3 mg/m<sup>3</sup>

Hungary  $8 \text{ mg/m}^3$  STEL:  $16 \text{ mg/m}^3$  Ireland  $8 \text{ mg/m}^3$ 

5 ppm 5 ppm STEL: 10 ppm

STEL: 15 mg/m³ ftaly 5 ppm

8 mg/m<sup>3</sup> STEL: 10 ppm STEL: 15 mg/m<sup>3</sup>

Ceiling Limit Value 2 ppm 3.0 mg/m³

Latvia 5 ppm 8 mg/m³ STEL: 10 ppm STEL: 15 mg/m³

Netherlands 8 mg/m<sup>3</sup>

Poland STEL: 15 mg/m³ STEL: 10 mg/m³

5 mg/m<sup>3</sup>
Romania 5 ppm
8 mg/m<sup>3</sup>

STEL: 10 ppm STEL: 15 mg/m<sup>3</sup> MAC: 5 mg/m<sup>3</sup>

 Russia
 MAC: 5 mg/m³

 Slovakia
 5 ppm

 8.0 mg/m³
 5 ppm

 5 ppm
 7.6 mg/m³

STEL: 10 ppm STEL: 15 mg/m<sup>3</sup> 2 ppm

Switzerland 2 ppm 3 mg/m³ STEL: 4 ppm

U.S. - OSHA - Final PELs - Ceiling Limits

STEL: 6 mg/m³
5 ppm
7 mg/m³

OSHA PEL (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m<sup>2</sup>

(vacated) Ceiling: 7 mg/m<sup>3</sup>

Ceiling: 5 ppm Ceiling: 7 mg/m<sup>3</sup>

United Kingdom TWA: 1 ppm

Revision date 18-Mar-2022 Version 2

TWA: 2 mg/m<sup>3</sup> STEL: 5 ppm STEL: 8 mg/m<sup>3</sup>

**SODIUM CHLORIDE** 

Latvia 5 mg/m³
Russia MAC: 5 mg/m³

**SODIUM CHLORIDE** 

Pfizer Occupational Exposure

Product Name Linezolid Injection (Hospira, Inc.)

OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

Band (OEB):

8.2. Exposure controls

Engineering controls Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Page 7/14

**Environmental exposure controls** No information available.

Personal protective equipment Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in

the workplace and specific operational processes.

**Eye/face protection** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious protective clothing is recommended if skin contact with drug product is possible

and for bulk processing operations. (Protective clothing must meet the standards in

accordance with EN13982, ANSI 103 or international equivalent.).

**Respiratory protection**Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter).

(Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10

or international equivalent.)

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

# Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state Liquid Color Clear, colorless

Odor No information available.
Odor threshold No information available

Molecular formula Mixture
Molecular weight Mixture

Property Values 4.4-5.2

Melting point / freezing point No data available

Boiling point / boiling range

Flash point No information available

Page 8/14

Revision date 18-Mar-2022 Version 2

Evaporation rate No data available Flammability (solid, gas) No data available

Flammability Limit in Air
Upper flammability limit:
No data available

Lower flammability limit: No data available

No data available Vapor pressure Vapor density No data available No data available Relative density No data available Water solubility Solubility(ies) No data available Partition coefficient No data available **Autoignition temperature** No data available **Decomposition temperature** No data available Kinematic viscosity No data available **Dvnamic viscosity** No data available

Particle characteristics

Particle SizeNo information availableParticle Size DistributionNo information availableExplosive propertiesNo information available

Partition Coefficient: (Method, pH, Endpoint, Value)

Product Name Linezolid Injection (Hospira, Inc.)

Linezolid

Measured 6-8 Log D 0.55

# 9.2. Other information

No information available

#### 9.2.1. Information with regard to physical hazard classes

No information available

#### 9.2.2. Other safety characteristics

No information available

# Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

**Reactivity** No data available.

10.2. Chemical stability

**Stability** Stable under normal conditions.

**Explosion data** 

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

**Conditions to avoid** Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

**Incompatible materials**As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

# Section 11: TOXICOLOGICAL INFORMATION

Product Name Linezolid Injection (Hospira, Inc.)

#### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

The information included in this section describes the potential hazards of the individual **General Information:** 

ingredients

Repeat-dose studies in animals have shown a potential to cause adverse effects on Long Term:

reproductive system the developing fetus.

**Known Clinical Effects:** The most common adverse effects reported with clinical use were diarrhea, nausea, rash,

and vomiting. Effects on blood and blood-forming organs have also occurred.

Page 9/14

Version 2

Acute toxicity Serious eye damage/eye irritation

Revision date 18-Mar-2022

Skin corrosion/irritation Respiratory or skin sensitization STOT - single exposure STOT - repeated exposure Reproductive toxicity Germ cell mutagenicity Carcinogenicity

Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Linezolid

Rat (F) Oral Minimum Lethal Dose 5000 mg/kg Rat (M) Oral Minimum Lethal Dose > 5000 mg/kg Dog Oral Minimum Lethal Dose > 2000 mg/kg

Citric acid

Mouse Oral LD50 5400 mg/kg

Sodium hydroxide

**Aspiration hazard** 

Mouse IP LD50 40 mg/kg

**SODIUM CHLORIDE** 

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>

Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Citric acid	= 3 g/kg (Rat)	> 2000 mg/kg (Rat)	-
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg ( Rabbit )	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg ( Rabbit )	> 42 mg/L (Rat) 1 h

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not

achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Linezolid

Eye Irritation Rabbit Minimal Skin Irritation Rabbit Minimal

Antigenicity- Passive cutaneous anaphylaxis Mouse Negative

Antigenicity- Active anaphylaxis Guinea Pig Negative

Citric acid

Eye Irritation Rabbit Severe Skin Irritation Rabbit Mild

# Sodium hydroxide

PZ03154

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

### + Hydrochloric Acid

Skin irritation Severe

Eve irritation Severe

# SODIUM CHLORIDE

Skin irritation Rabbit Mild Eye irritation Rabbit Mild

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Linezolid

1 Month(s) Rat Oral 20 mg/kg/day NOAEL Blood forming organs, Blood 3 Month(s) Rat Oral 10 mg/kg/day NOAEL Blood forming organs, Blood

1 Month(s) Dog Oral 20 mg/kg/day NOAEL Blood forming organs, Blood, Gastrointestinal system 3 Month(s) Dog Oral 20 mg/kg/day NOAEL Blood forming organs, Blood, Gastrointestinal system

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)) Linezolid

Reproductive & Fertility Rat Oral 50 mg/kg/day NOAEL Fertility

Embryo / Fetal Development Rat Oral 2.5 mg/kg/day NOAEL Fetotoxicity, Not Teratogenic

15 mg/kg/day NOAEL Maternal Toxicity Embryo / Fetal Development Rat Oral

Embryo / Fetal Development Mouse Oral 150 mg/kg/day NOAEL Fetotoxicity, Maternal Toxicity, Not Teratogenic

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result) Linezolid

In Vitro Unscheduled DNA Synthesis Negative Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

In Vivo Micronucleus Mouse Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) Salmonella

Negative

In Vivo Micronucleus Rat Negative

None of the components of this formulation are listed as a carcinogen by IARC, NTP or Carcinogenicity

+ Hydrochloric Acid

IARC Group 3 (Not Classifiable)

#### 11.2. Information on other hazards

#### 11.2.1. Endocrine disrupting properties

No information available. **Endocrine disrupting properties** 

11.2.2. Other information

Other adverse effects No information available.

#### Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should

be avoided.

#### **12.1. Toxicity**

### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

# Linezolid

Daphnia magna (Water Flea) OECD EC50 48 hours > 100 mg/L

Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 hours > 1.4 mg/L Anabaena flos-aguae (Cyanobacteria) Algae OECD ErC50 96 hours

PZ03154

Page 10 / 14 Version 2

Page 11/14

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

Revision date 18-Mar-2022 Version 2

Anabaena flos-aquae (Cyanobacteria) OECD NOEC 96 hours 1.0 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Linezolid

Activated sludge OECD EC50 / EC15 > 1000 mg/L

Aspergillus niger (Fungus) OECD MIC 600 mg/L

Trichoderma viride (Fungus) OECD MIC > 1000 mg/L

Clostridium perfingens (Bacterium) OECD MIC 2 mg/L

Bacillus subtilis (Bacterium) OECD MIC 0.4 mg/L

# Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

Linezolid

Pimephales promelas (Fathead Minnow) OECD 32 Day(s) NOEC 9.9 mg/L Sublethal effects Daphnia magna (Water Flea) OECD 21 Day(s) NOEC 24 mg/L Reproduction Ceriodaphnia dubia (Daphnids) OECD 7 Day(s) NOEC 31 mg/L Reproduction, Survival

# 12.2. Persistence and degradability

#### Persistence and degradability

# <u>Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)</u> Linezolid

OECD Activated sludge Die-away, Mineralization (CO2 Evolution) 84 % in 28 Day(s)

OECD Activated sludge Mineralization (CO2 Evolution) -3.4% Not readily biodegradable

OECD Water - Sediment (various) Mineralization (CO2 Evolution) 44 - 52.7 % in 102 Day(s)

OECD Water - Sediment (various) Total System DT50 23 - 24.7 Day(s)

#### 12.3. Bioaccumulative potential

#### Bioaccumulation

# Partition Coefficient: (Method, pH, Endpoint, Value)

Linezolid

Measured 6-8 Log D 0.55

#### 12.4. Mobility in soil

### Mobility in soil

Sorption:

Linezolid (165800-03-3)

<u>Method</u>	Inoculum	End Point	Result
OECD	Activated sludge	Kd	3.0
OECD	Activated sludge	Koc	8.6
OECD	Soil (various)	Kd (Geometric mean)	18.8
OECD	Soil (various)	Koc (Geometric mean)	922

#### 12.5. Results of PBT and vPvB assessment

# PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Citric acid	The substance is not PBT / vPvB
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does
	not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does
	not apply
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does
	not apply

Page 12 / 14

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

# 12.6. Endocrine disrupting properties

No information available. **Endocrine disrupting properties** 

#### 12.7. Other adverse effects

No information available.

### Section 13: DISPOSAL CONSIDERATIONS

#### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

# Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

**UN number:** Not applicable **UN proper shipping name:** Not applicable Transport hazard class(es): Not applicable Not applicable Packing group: **Environmental Hazard(s):** Not applicable

Not applicable Special precautions for user:

# Section 15: REGULATORY INFORMATION

#### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus % Not Listed Not Listed California Proposition 65 **TSCA** Present **EINECS** 231-791-2 **AICS** Present

**Dextrose** 

CERCLA/SARA Section 313 de minimus % Not Listed **California Proposition 65** Not Listed Not Listed **EINECS** Present **AICS** 

Linezolid

CERCLA/SARA Section 313 de minimus % Not Listed **California Proposition 65** Not Listed **EINECS** Not Listed Standard for Uniform Scheduling of Medicines and Schedule 4

Poisons (SUSMP)

Citric acid

PZ03154

Version 2

Page 13 / 14

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

Revision date 18-Mar-2022 Version 2

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 201-069-1
AICS Present

Sodium hydroxide

CERCLA/SARA Section 313 de minimus % Not Listed **Hazardous Substances RQs** 1000 lb **California Proposition 65** Not Listed **TSCA** Present 215-185-5 **EINECS AICS** Present Standard for Uniform Scheduling of Medicines and Schedule 5 Poisons (SUSMP) Schedule 6

+ Hydrochloric Acid

CERCLA/SARA Section 313 de minimus % 1.0 % **Hazardous Substances RQs** 5000 lb California Proposition 65 Not Listed **TSCA** Present **EINECS** 231-595-7 **AICS** Present Schedule 5 Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) Schedule 6

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 231-598-3
AICS Present

#### **France**

Occupational Illnesses (R-463-3, France)

occupational infecces (it 400 c; i failed)		
Chemical name	French RG number	Title
SODIUM CHLORIDE	RG 78	-
7647-14-5		

#### **European Union**

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents

#### Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH	Substance subject to authorization per
	Annex XVII	REACH Annex XIV
Citric acid - 77-92-9	Use restricted. See item 75.	
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

#### **Persistent Organic Pollutants**

Not applicable

#### Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	L	_ower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0		25	250

Page 14/14

Product Name Linezolid Injection (Hospira, Inc.) Revision date 18-Mar-2022

Revision date 18-Mar-2022 Version 2

Plant protection products directive (91/414/EEC)

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

#### **EU - Biocides**

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algaecides not intended
	for direct application to humans or animals

# Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

#### 15.2. Chemical safety assessment

Chemical Safety Report No information available

### Section 16: OTHER INFORMATION

#### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of H-Statements referred to under section 3

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure. Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation. Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage. Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life. Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual

ingredients.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

Company/Undertaking. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

Revision date 18-Mar-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.